Csenge Advisory Group’s Cytokinetics CYTK Stock Holding History

Csenge Advisory Group’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-17	Closed	–	–	488
2018 Q3	$0	Buy	+17	New	+$136	﹤0.01%	1158

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

LPU

Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Csenge Advisory Group's CYTK Position: Q4 2018 in Review

Csenge Advisory Group sold out of Cytokinetics (CYTK) in Q4 2018, closing a stake of 17 shares.

Csenge Advisory Group first reported a position in CYTK in Q3 2018 and held it in 1 quarter. The position peaked at $0 in Q3 2018. 137 funds tracked by Wall St. Rank hold CYTK as of Q4 2018.

Csenge Advisory Group reported no remaining Cytokinetics position as of Q4 2018 after selling out during the quarter.
Csenge Advisory Group sold 17 Cytokinetics shares in Q4 2018.
Csenge Advisory Group first reported a position in Cytokinetics in Q3 2018 and held it in 1 quarter.
Csenge Advisory Group's Cytokinetics position peaked at $0 in Q3 2018.
137 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2018.

Based on Csenge Advisory Group's 13F filing for Q4 2018, filed 7 Feb 2019.